| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8219305 | International Journal of Radiation Oncology*Biology*Physics | 2014 | 7 Pages |
Abstract
Loss of DAB2IP is a potent biomarker that portends worse outcome despite definitive radiation therapy for patients with high-risk prostate cancer. Enhancer of zeste homolog 2 is expressed in most high-risk tumors and is a less potent discriminator of outcome in this study. The DAB2IP status in combination with degree of EZH2 expression may be useful for determining patients with worse outcome within the high-risk prostate cancer population.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Corbin BS, Vasu MD, Payal MD, Jingsheng PhD, David MD, Manzerul MS, Xian-Jin PhD, David MD, PhD, Lan PhD, Jer-Tsong PhD, Debabrata PhD, D. W. Nathan MD, PhD,